Correction to: Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study
Invest New Drugs. 2022 Apr;40(2):461.
doi: 10.1007/s10637-021-01192-5.
1 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA. theink@ohsu.edu.
2 Division of Hematology and Medical Oncology, Oregon Health and Science University/ Knight Cancer Institute, Portland, OR, USA. theink@ohsu.edu.
3 Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA.
4 Karyopharm Therapeutics, Newton, MA, USA.
5 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
6 Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
7 Department of Thoracic Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.